Ruxolitinib 2 mg/mL oral suspension
Ingredients
| Ingredient | Role | For 100 mL |
|---|---|---|
| Ruxolitinib (as phosphate) | active | 200 mg |
| Inorpha ready-to-use oral vehicle | vehicle | q.s. to 100 mL |
- Strength
- 2 mg/mL
- Starting material
- Ruxolitinib tablets
- Container
- See the study
Amounts are ClinDose's arithmetic from the study's concentration; follow the study for the method.
Storage and beyond-use date
| Storage | BUD | Basis |
|---|---|---|
| Refrigerated | 60 days | Cited stability study. Duration supported by the cited stability study for this formula, container, and storage. |
| Room temperature | 60 days | Cited stability study. Duration supported by the cited stability study for this formula, container, and storage. |
Only the storage conditions the source covers are listed. Use the BUD assistant for other cases. The BUD may not be later than any component's expiration date. Verify against the current official USP chapter.
Ingredient checks
No FDA compounding list or NIOSH flags for the active ingredient.
Source
Hinterlang M, Sebti M, Cotteret C, et al.. Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease. ScientificWorldJournal. 2022;2022:1931118. PMID 35694327. PMC9184215. License: CC BY (checked 2026-11-06). Read the article · DOI
For licensed clinicians. Use with clinical judgment.